Plain-English translation of NCT06014424 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether cannabidiol ()—a naturally derived, highly purified plant extract—can help reduce agitation in people with Alzheimer's disease. Agitation is a common and distressing symptom that can lead to falls, weight loss, and caregiver stress. Researchers want to see if this medication might be a safer and more effective option than current treatments.
Many people with Alzheimer's experience agitation, but existing treatments don't work well for everyone and raise safety concerns. This trial exists to find safer, more effective ways to help patients and reduce the burden on family caregivers.
You likely qualify if…
You likely don't qualify if…
You would participate for about 23 weeks total. You'll take either the medication or a placebo for the first 19 weeks, then switch to the opposite treatment for another period—this crossover design helps researchers fairly compare both. During this time, you'll have about 12 in-person visits (roughly every 2 weeks) and 8 weekly phone check-ins, then 4 weeks of follow-up. Your caregiver will be involved in visits and assessments throughout.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Canada